Your browser doesn't support javascript.
loading
Irradiation-induced nasopharyngeal necrosis (INN) in newly diagnosed nasopharyngeal carcinoma treated by intensity-modulated radiation therapy: clinical characteristics and the influence of treatment strategies.
Xu, Yi; Liu, Yang; Wang, Zekun; Wang, Jingbo; Zhang, Jianghu; Chen, Xuesong; Wu, Runye; Liu, Qingfeng; Qu, Yuan; Wang, Kai; Huang, Xiaodong; Luo, Jingwei; Gao, Li; Xu, Guozhen; Zhang, Ye; Yi, Junlin.
Afiliação
  • Xu Y; Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC), No17, Panjiayuan Nanli, Chaoyang District, Beijing, 100021, People's Republic of China.
  • Liu Y; Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC), No17, Panjiayuan Nanli, Chaoyang District, Beijing, 100021, People's Republic of China.
  • Wang Z; Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC), No17, Panjiayuan Nanli, Chaoyang District, Beijing, 100021, People's Republic of China.
  • Wang J; Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC), No17, Panjiayuan Nanli, Chaoyang District, Beijing, 100021, People's Republic of China.
  • Zhang J; Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC), No17, Panjiayuan Nanli, Chaoyang District, Beijing, 100021, People's Republic of China.
  • Chen X; Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC), No17, Panjiayuan Nanli, Chaoyang District, Beijing, 100021, People's Republic of China.
  • Wu R; Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC), No17, Panjiayuan Nanli, Chaoyang District, Beijing, 100021, People's Republic of China.
  • Liu Q; Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC), No17, Panjiayuan Nanli, Chaoyang District, Beijing, 100021, People's Republic of China.
  • Qu Y; Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC), No17, Panjiayuan Nanli, Chaoyang District, Beijing, 100021, People's Republic of China.
  • Wang K; Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC), No17, Panjiayuan Nanli, Chaoyang District, Beijing, 100021, People's Republic of China.
  • Huang X; Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC), No17, Panjiayuan Nanli, Chaoyang District, Beijing, 100021, People's Republic of China.
  • Luo J; Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC), No17, Panjiayuan Nanli, Chaoyang District, Beijing, 100021, People's Republic of China.
  • Gao L; Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC), No17, Panjiayuan Nanli, Chaoyang District, Beijing, 100021, People's Republic of China.
  • Xu G; Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC), No17, Panjiayuan Nanli, Chaoyang District, Beijing, 100021, People's Republic of China.
  • Zhang Y; Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC), No17, Panjiayuan Nanli, Chaoyang District, Beijing, 100021, People's Republic of China. drzye1983
  • Yi J; Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC), No17, Panjiayuan Nanli, Chaoyang District, Beijing, 100021, People's Republic of China. yijunlin1
Radiat Oncol ; 17(1): 13, 2022 Jan 21.
Article em En | MEDLINE | ID: mdl-35062991
PURPOSE: To define the clinical characteristics of irradiation-induced nasopharyngeal necrosis (INN) after intensity-modulated radiotherapy (IMRT) and identify the influence of treatment strategies on INN in primary nasopharyngeal carcinoma (NPC) patients. PATIENTS AND METHODS: From 2008 to 2019, NPC patients pathologically diagnosed with INN after primary IMRT were reviewed. Those patients were matched with propensity scores for patients without INN in our center. The impact of treatment strategies on INN occurrence was assessed using univariate and multivariate logistic regression analysis. RESULTS: The incidence rate of INN was 1.9% among the primary NPC population, and 53 patients with INN were enrolled. Headache and foul odor were the main symptoms, and 71.7% of cases had pseudomembrane during or at the end of radiotherapy. All patients were in early or middle stage INN, and no one presented with skull-based osteoradionecrosis. Then 212 non-INN patients were included based on propensity scores match. Overall survival (p = 0.248) and progression-free survival (p = 0.266) curves were similar between the INN and non-INN groups. Treatment strategies including combining chemotherapy or molecular targeted therapy with radiotherapy were not associated with INN occurrence, while boost dose (OR 7.360; 95% CI 2.301-23.547; p = 0.001) was a predictor factor for it. However, the optimal threshold for an accumulated dose to predict INN's occurrence was failed to determine. CONCLUSION: In the IMRT era, the severity of INN in primary NPC patients is lessened. This study showed that treatment strategies contributed little to develop INN, while the accumulated dose of radiation may relate to its occurrence.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Lesões por Radiação / Nasofaringe / Neoplasias Nasofaríngeas / Radioterapia de Intensidade Modulada / Carcinoma Nasofaríngeo Tipo de estudo: Diagnostic_studies / Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adolescent / Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Radiat Oncol Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Lesões por Radiação / Nasofaringe / Neoplasias Nasofaríngeas / Radioterapia de Intensidade Modulada / Carcinoma Nasofaríngeo Tipo de estudo: Diagnostic_studies / Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adolescent / Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Radiat Oncol Ano de publicação: 2022 Tipo de documento: Article